Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates

By Yahoo! Finance | Jul 26, 2024 at 06:46 AM EST

Viking Therapeutics reported a narrower Q2 loss, with no approved products yet. Expenses increased due to drug candidate manufacturing. The company's promising drug VK2735 for obesity is advancing to phase III development. VKTX stock surged post-positive pipeline updates.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.